Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...

Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

Eikon Therapeutics has added to its already copious cash reserves with a $351 million fourth-round financing to fund a ...

Eikon is pursuing a number of clinical-stage programs including EIK1001, which is currently in Phase III testing for advanced melanoma.

Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer. Association of ...

The funding, led by existing and new investors, is expected to support Eikon’s efforts to integrate advanced computing, ...

Allarity has consistently maintained that these claims were without merit. The case against all defendants has been dismissed with each party bearing its own legal costs and fees. No settlement or ...

Synnovation’s lead candidate and potentially best-in-class PARP1 selective program, SNV1521, entered a Phase I trial in January of 2024. The SNV4818 Phase I trial, which is being led by Timothy ...